Clinical trial
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or…
NCT00442871 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00442871 |
|---|---|
| Title | Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment |
| Official title | An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg Eltrombopag in Healthy Subjects and in Subjects With Mild, Moderate, or Severe Renal Impairment |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopaenic, Idiopathic |
| Intervention type | Drug |
| Interventions | eltrombopag |
| Enrollment | 29 |
| Start date | Sep 28, 2006 |
| Primary completion | Jan 3, 2008 |
| Completion | Jan 3, 2008 |
| First posted | Mar 5, 2007 |
| Last update posted | Nov 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: